Author:
Koster Matthew J.,Achenbach Sara J.,Crowson Cynthia S.,Maradit-Kremers Hilal,Matteson Eric L.,Warrington Kenneth J.
Abstract
Objective.To determine the healthcare use and direct medical cost of giant cell arteritis (GCA) in a population-based cohort.Methods.A well-defined, retrospective population-based cohort of Olmsted County, Minnesota, USA, residents diagnosed with GCA from 1982–2009 was compared to a matched referent cohort from the same population. Standardized cost data (inflation-adjusted to 2014 US dollars) for 1987–2014 and outpatient use data for 1995–2014 were obtained. Use and costs were compared between cohorts through signed-rank paired tests, McNemar’s tests, and quantile regression models.Results.Significant annual differences in outpatient costs were observed for patients with GCA in each of the first 4 years (median differences: $2085, $437, $382, $388, respectively). In adjusted analyses, median incremental cost attributed to GCA over a 5-year period was $4662. Compared with matched referent subjects, patients with GCA had higher use of laboratory visit-days annually for each of the first 3 years following incidence/index date, and increased outpatient physician visits for years 0–1, 1–2, and 3–4. Patients with GCA had significantly more radiology visit-days in years 0–1, 3–4, and 4–5, and more ophthalmologic procedures/surgery in years 0–1, 1–2, 2–3, and 4–5 compared to non-GCA. Emergency medicine visits, musculoskeletal, and cardiovascular procedures/surgery were similar between GCA and non-GCA groups throughout the study period.Conclusion.Direct medical outpatient costs were increased in the month preceding and in the first 4 years following GCA diagnosis. Higher use of outpatient physician, laboratory, and radiology visits, and ophthalmologic procedures among these patients accounts for the increased cost of care.
Publisher
The Journal of Rheumatology
Subject
Immunology,Immunology and Allergy,Rheumatology
Reference25 articles.
1. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997
2. Centers for Disease Control and Prevention . Chronic Disease Cost Calculator Version 2. [Internet. Accessed March 31, 2017.] Available from: www.cdc.gov/chronicdisease/calculator
3. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid arthritis;Furneri;Clin Exp Rheumatol,2012
4. The economic burden of systemic lupus erythematosus
5. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献